Boston Scientific Corporation BSX-PA NYSE

Boston Scientific Corporation (BSX-PA) generated $4.53B in operating cash flow for fiscal year 2025. After capital expenditures of $876M, free cash flow was $3.66B.

Free cash flow margin was 18.2% of revenue. Cash conversion ratio was 1.57x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (86/100, Pass) — $3.66B (18.2% FCF margin) supports a durable competitive advantage
• INCOME (55/100) — Cash conversion ratio was 1.57x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 76/100 with 5/7 criteria passed.